With Congress considering legislation to allow Medicare to use its bargaining power to negotiate lower drug prices, large pharmaceutical companies are once again waging a campaign that contends that doing so would seriously harm the development of breakthrough drugs. This is not true. Smaller companies now account for the lion’s share of such breakthroughs. The key to supporting drug innovation is to increase NIH funding of the efforts that gives rise to these new companies, cut the costs and accelerate the speed of clinical trials, and reform patent law.
Legislation giving Medicare the ability to negotiate drug prices in …
Related posts:
Stefan Pietrobono's Blueprint for Success: Marketing Strategy Masterclass at 1StartupWorld
Strategies for Securing Startup Funding
Unleashing the Future: Navigating the Convergence of Podcasting and AI in Corporate Communications
Chip Rogers of AHLA to Illuminate the 2024 Hotel Landscape at 1TourismWorld Conference
